These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26112144)

  • 21. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa: effect on cell death and the natural history of Parkinson's disease.
    Olanow CW
    Mov Disord; 2015 Jan; 30(1):37-44. PubMed ID: 25502620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
    Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
    Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
    Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs.
    Giorgioni G; Claudi F; Ruggieri S; Ricciutelli M; Palmieri GF; Di Stefano A; Sozio P; Cerasa LS; Chiavaroli A; Ferrante C; Orlando G; Glennon RA
    Bioorg Med Chem; 2010 Mar; 18(5):1834-43. PubMed ID: 20153654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tea and Parkinson's disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits.
    Dutta D; Mohanakumar KP
    Neurochem Int; 2015 Oct; 89():181-90. PubMed ID: 26271432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The L-amino acid carrier inhibitor 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH) reduces L-dopa-elicited responses in dopaminergic neurons of the substantia nigra pars compacta.
    Sebastianelli L; Ledonne A; Marrone MC; Bernardi G; Mercuri NB
    Exp Neurol; 2008 Jul; 212(1):230-3. PubMed ID: 18501350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.
    Baul HS; Manikandan C; Sen D
    Brain Res Bull; 2019 Mar; 146():244-252. PubMed ID: 30664919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinson's Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors.
    Montioli R; Voltattorni CB; Bertoldi M
    Curr Drug Metab; 2016; 17(5):513-8. PubMed ID: 27025882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. H2O2- or l-DOPA-injured dopaminergic neurons trigger the release of soluble mediators that up-regulate striatal GDNF through different signalling pathways.
    Fonseca CP; Gama S; Saavedra A; Baltazar G
    Biochim Biophys Acta; 2014 Jul; 1842(7):927-34. PubMed ID: 24632468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease.
    Robelet S; Melon C; Guillet B; Salin P; Kerkerian-Le Goff L
    Eur J Neurosci; 2004 Sep; 20(5):1255-66. PubMed ID: 15341597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
    Hornykiewicz O
    Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.